Ximena Arcila-Londono

Ximena Arcila-Londono

Auto-generated profile, based on publicly available information

Ximena Arcila-Londono

Harry J. Hoenselaar ALS Clinic, Henry Ford University, Detroit, MI United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Closed access
ABAlex Berger
Alex Berger
MLMatteo Locatelli
Matteo Locatelli
XAXimena Arcila-Londono
Ximena Arcila-Londono
GHGhazala Hayat
Ghazala Hayat
NONicholas Olney
Nicholas Olney
TCThe Pooled Resource Open-Access ALS Clinical Trials Consortium
The Pooled Resource Open-Access ALS Clinical Trials Consortium
Amyotrophic lateral sclerosis (ALS) is a rare disease with urgent need for improved treatment. Despite the acceleration of research in recent years, there is a need to understand the full natural history of the disease. As only 40% of people living with ALS are eligible for typical clinical trials, clinical trial datasets may not generalize to the full ALS population. While biomarker and cohort studies have more generous inclusion criteria, these too may not represent the full range of phenotypes, particularly if the burden for participation is high. To permit a complete understanding of the heterogeneity of ALS, comprehensive data on the full range of people with ALS is needed. The ALS Natural History Consortium (ALS NHC) consists of nine ALS clinics and was created to build a comprehensive dataset reflective of the ALS population. At each clinic, most patients are asked to participate and about 95% do. After obtaining consent, a minimum dataset is abstracted from each participant's electronic health record. Participant burden is therefore minimal. Data on 1925 ALS patients were submitted as of 9 December 2022. ALS NHC participants were more heterogeneous relative to anonymized clinical trial data from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. The ALS NHC includes ALS patients of older age of onset and a broader distribution of El Escorial categories, than the PRO-ACT database. ALS NHC participants had a higher diversity of diagnostic and demographic data compared to ALS clinical trial participants.Key MessagesWhat is already known on this topic: Current knowledge of the natural history of ALS derives largely from regional and national registries that have broad representation of the population of people living with ALS but do not always collect covariates and clinical outcomes. Clinical studies with rich datasets of participant characteristics and validated clinical outcomes have stricter inclusion and exclusion criteria that may not be generalizable to the full ALS population.What this study adds: To bridge this gap, we collected baseline characteristics for a sample of the population of people living with ALS seen at a consortium of ALS clinics that collect extensive, pre-specified participant-level data, including validated outcome measures.How this study might affect research, practice, or policy: A clinic-based longitudinal dataset can improve our understanding of the natural history of ALS and can be used to inform the design and analysis of clinical trials and health economics studies, to help the prediction of clinical course, to find matched controls for open label extension trials and expanded access protocols, and to document real-world evidence of the impact of novel treatments and changes in care practice.

12 September 2018 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
WAWissam Al-Janabi
Wissam Al-Janabi
RKRenee Krebs
Renee Krebs
XAXimena Arcila-Londono
Ximena Arcila-Londono
IZIram Zaman
Iram Zaman
BABashiruddin K Ahmad
Bashiruddin K Ahmad
Background: Glioblastoma multiforme (GBM) is a highly malignant glial tumour classified by the World Health Organization (WHO) as a stage IV astrocytoma. It varies in shape and size and can be cystic, vascular and necrotic. It often appears as a ring-enhancing lesion on magnetic resonance imaging (MRI). The most common symptoms of GBM, such as headache, vomiting and seizures, are due to increased intracranial pressure. The objective of this case report is to describe an atypical presentation of GBM. Case Report: A 53-year-old woman of Italian origin presented with a 2-week history of lack of coordination in her hands and some difficulty in speech. Electromyography for assessment of her arms and cranial bulbar function was normal. However, 2 days later, the patient presented to the emergency department with progressive weakness in her left arm and leg as well as difficulty in speech. Mild left facial asymmetry was noted. A brain MRI revealed a right frontal mass. Stereotactic surgical resection was performed 2 days later, and biopsy confirmed the diagnosis of GBM. Although headache and other features of raised intracranial pressure are the most common initial symptoms of GBM, any atypical neurological or psychiatric presentation in an adult patient should raise suspicion for this tumour. Conclusion: Careful analysis of an adult with atypical signs and symptoms along with thorough review of radiological tests will facilitate early diagnosis of dangerous tumours such as GBM.

27 October 2026 in Muscle & Nerve
Verified
Journal Article
Open access
KDKelly Anne Duffy
Kelly Anne Duffy
KGKelly Gwathmey
Kelly Gwathmey
DSDavid Schneck
David Schneck
AAAndres Arguedas
Andres Arguedas
AXAnnette Xenopoulos‐Oddsson
Annette Xenopoulos‐Oddsson
DWDavid Walk
David Walk
Introduction/Aims: Study of clinical milestones, particularly intermediate events like loss of ambulation, in large amyotrophic lateral sclerosis (ALS) cohorts is limited. Here, we leverage the ALS Natural History Consortium dataset to evaluate the time‐to‐event for several outcomes and prognostic factors that predict risk. Methods: Longitudinal data from 1950 participants were used in time‐to‐event analyses based on time from diagnosis. Outcomes were gastrostomy, loss of ambulation, loss of useful speech, non‐invasive ventilation (NIV) usage, and death equivalent (death or mechanical ventilation). Median times‐to‐event were calculated along with Kaplan–Meier curves. Cox proportional hazards models for each outcome estimated (through adjusted hazard ratios [HR]) the impact of several prognostic factors, including sex, region of onset, age at diagnosis, and the initial rate of change (delta‐FRS) in ALS Functional Rating Scale‐Revised (ALSFRS‐R) scores. Results: Estimated median times‐to‐event for clinical outcomes ranged from 1.44 to 6.21 years, with a median time to death equivalent of 2.12 years. A higher delta‐FRS was the greatest risk factor for all outcomes (HRs between 2.01 and 3.05). Limb onset decreased risk of loss of speech, NIV use, gastrostomy, and death equivalent (HRs 0.41–0.78). Older age at diagnosis increased risk of gastrostomy, NIV use, and death equivalent (HRs 1.08–1.27). Discussion: These findings further inform expectations of time to various outcomes, especially rarely investigated intermediate events, and their risk factors. The importance of progression rate supports other recent findings, highlighting delta‐FRS as a key prognostic factor with potential utility in clinical trial designs.